✦ LIBER ✦

Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Xience V Everolimus-Eluting Coronary Stent

✍ Scribed by Rebecca Torguson; Ron Waksman

Book ID: 113445152
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 289 KB
Volume: 102
Category: Article
ISSN: 0002-9149
DOI: 10.1016/j.amjcard.2008.08.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Overview of the 2006 Food and Drug Admin

Overview of the 2006 Food and Drug Administration Circulatory System Devices Panel meeting on drug-eluting stent thrombosis

✍ Tina L. Pinto Slottow; Ron Waksman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

## Abstract Drug‐eluting stents (DES) seemed likely to mitigate the problem of restenosis and have become the predominant stent deployed during percutaneous coronary intervention (PCI). Sustained concerns about the rate of stent thrombosis (ST), particularly very late ST (>1 year following PCI) led

Overview of the 2011 food and drug admin

Overview of the 2011 food and drug administration's circulatory system devices panel of the medical devices advisory committee meeting on the Zilver® PTX® Drug-Eluting peripheral stent

✍ Dvir, Danny; Torguson, Rebecca; Waksman, Ron 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 252 KB

Overview of the 2013 Food and Drug Admin

Overview of the 2013 Food and Drug Administration Circulatory System Devices Panel Meeting on the MitraClip Delivery System

✍ Minha, S.; Torguson, R.; Waksman, R. 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 631 KB

Overview of the 2011 Food and Drug Admin

Overview of the 2011 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee Meeting on the CardioMEMS Champion Heart Failure Monitoring System

✍ Loh, Joshua P.; Barbash, Israel M.; Waksman, Ron 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 709 KB

Comparison of Everolimus-Eluting and Pac

Comparison of Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) Randomized Trials

✍ Dean J. Kereiakes; Krishnankutty Sudhir; James B. Hermiller; Paul C. Gordon; Joa 📂 Article 📅 2010 🏛 American College of Cardiology 🌐 English ⚖ 939 KB

Summary of the Food and Drug Administrat

Summary of the Food and Drug Administration's Circulatory System Devices Advisory Panel Meeting: December 7 and 8, 2006, Gaithersburg, MD

✍ Kathryn C. Coons 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 79 KB